Compass Therapeutics, Inc. is a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics to treat multiple human diseases. Compass’s scientific focus is on the relationship between angiogenesis and the immune system. The company pipeline includes novel product candidates that leverage understanding of the tumor microenvironement, including both angiogenesis-targeted agents and immune-oncology focused agents. These product candidates are designed to optimize critical components required for an effective anti-tumor response to cancer. These include modulation of the microvasculature via angiogenesis-targeted agents; induction of a potent immune response via activators on effector cells in the tumor microenvironment; and alleviation of immunosuppressive mechanisms used by tumors to evade immune surveillance. Compass plans to advance its product candidates through clinical development as both standalone therapies and in combination with its proprietary drug candidates as long as continued development is supported by clinical and nonclinical data. The company was founded in 2014 and is headquartered in Boston, Massachusetts.
To learn more, visit www.compasstherapeutics.com
To learn more, visit www.compasstherapeutics.com
Location: United States, Massachusetts, Boston
Employees: 11-50
Total raised: $312M
Founded date: 2014
Investors 6
| Date | Name | Website |
| 06.03.2022 | Foresite C... | foresiteca... |
| - | F-Prime Ca... | fprimecapi... |
| - | OrbiMed | orbimed.co... |
| - | Montrose C... | montroseca... |
| - | Eight Road... | eightroads... |
| - | GV | gv.com |
Funding Rounds 3
| Date | Series | Amount | Investors |
| 24.06.2020 | - | $60M | - |
| 12.07.2018 | Series A | $132M | - |
| 08.07.2015 | - | $120M | - |
Mentions in press and media 18
| Date | Title | Description |
| 12.08.2024 | Compass Therapeutics Reports 2024 Second Quarter Financial Results and Provides Corporate Update | Completed enrollment of the 150 patients in the COMPANION-002 Study, a Phase 2/3 trial of CTX-009 (DLL4 and VEGF-A bispecific antibody) plus paclitaxel versus paclitaxel monotherapy in patients with previously treated, unresectable advanced... |
| 19.01.2023 | Compass Therapeutics Announces that the Phase 2 Data of CTX-009 in Combination with Paclitaxel in Patients with Biliary Tract Cancers (BTC) will be Presented at the ASCO GI Cancers Symposium on Januar... | /EIN News/ -- Compass to Host Investor Event on Monday, January 23rd at 8:30am ET CTX-009 in combination with paclitaxel demonstrated a 37.5% overall response rate (ORR) in 24 patients with BTC treated in the second- and third- line setting... |
| 05.03.2021 | Compass Therapeutics Reports Fourth Quarter and Full Year 2020 Financial Results and Provides Business Update | BOSTON--(BUSINESS WIRE)--Mar 5, 2021-- Compass Therapeutics, Inc. (OTCQB: CMPX), a clinical-stage biotechnology company developing proprietary antibody therapeutics intended to engage the immune system to treat both solid tumors and hematol... |
| 04.03.2021 | Compass Therapeutics to Commence Trading on the OTCQB Venture Market Under the Symbol “CMPX” | BOSTON--(BUSINESS WIRE)--Mar 4, 2021-- Compass Therapeutics, Inc. (OTCQB: CMPX), a clinical-stage biotechnology company developing proprietary antibody therapeutics intended to engage the immune system to treat both solid tumors and hematol... |
| 24.06.2020 | Compass Therapeutics Completes Reverse Merger and Closes $60 Million Private Placement | - |
| 23.06.2020 | Compass Therapeutics Completes Reverse Merger and Closes $60 Million Private Placement | - |
| 13.07.2018 | Term Sheet – Friday, July 13 | EDUCATION Happy Friday. Polina returns Monday. Reach me lucinda.shen@fortune.com. Paid Content Securing the enterprise without boundaries From ExtraHop Today, Austin-based pi-top, a learn-to-code startup, raised $16 million in funding led b... |
| 12.07.2018 | Compass Therapeutics Closes on Series A Financing Totaling $132 Million | - |
| 12.07.2018 | Compass Therapeutics launches with $132M to advance a clutch of antibodies | Compass Therapeutics is coming out of stealth with $132 million in series A cash, 15 prospects in preclinical development and a lead oncology asset poised to enter the clinic in 2019. It's keeping specific targets and indications under wrap... |
| 12.07.2018 | Compass Therapeutics Completes $132M Series A Financing | Compass Therapeutics, a Cambridge, MA-based biotechnology company committed to comprehensively drugging the human immune system, closed the final $49m tranche of its $132m Series A financing. The round was led by OrbiMed Advisors and includ... |
Show more